CG
TAK icon

Cutler Group’s Takeda Pharmaceutical TAK Stock Holding History

Cutler Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,244
Closed -$35.7K – 4695
2022
Q4 		$35K Buy
2,244
+300
+15% +$4.19K ﹤0.01% 1824
2022
Q3 		$25K Buy
+1,944
New +$27K ﹤0.01% 2447
2022
Q2 		– Sell
-3,200
Closed -$45.7K – 5656
2022
Q1 		$45K Buy
3,200
+3,000
+1,500% +$44K ﹤0.01% 2347
2021
Q4 		$2K Sell
200
-210
-51% -$2.95K ﹤0.01% 4832
2021
Q3 		$6K Sell
410
-1,900
-82% -$31.9K ﹤0.01% 4359
2021
Q2 		$38K Buy
+2,310
New +$39.3K ﹤0.01% 2733
2021
Q1 		– Sell
-1,000
Closed -$18K – 6258
2020
Q4 		$18K Hold
1,000
– – ﹤0.01% 2765
2020
Q3 		$17K Hold
1,000
– – ﹤0.01% 2591
2020
Q2 		$17K Hold
1,000
– – ﹤0.01% 2515
2020
Q1 		$15K Sell
1,000
-7,302
-88% -$132K ﹤0.01% 2504
2019
Q4 		$163K Sell
8,302
-2,400
-22% -$45.9K 0.01% 932
2019
Q3 		$184K Sell
10,702
-11,089
-51% -$192K 0.02% 741
2019
Q2 		$385K Buy
+21,791
New +$397K 0.04% 416

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cutler Group's TAK Position: Q1 2023 in Review

Cutler Group sold out of Takeda Pharmaceutical (TAK) in Q1 2023, closing a stake of 2,244 shares — an estimated $35.7K sold.

Cutler Group first reported a position in TAK in Q2 2019 and held it in 13 quarters. The position peaked at $385K in Q2 2019. 300 funds tracked by Wall St. Rank hold TAK as of Q1 2023.

  • Cutler Group reported no remaining Takeda Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 2,244 Takeda Pharmaceutical shares in Q1 2023, an estimated $35.7K.
  • Cutler Group first reported a position in Takeda Pharmaceutical in Q2 2019 and held it in 13 quarters.
  • Cutler Group's Takeda Pharmaceutical position peaked at $385K in Q2 2019.
  • 300 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.